Danaher upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs upgraded Danaher (DHR) to Buy from Neutral with a $260 price target Since the firm’s downgrade at the end of 2023, FY25 consensus estimates have come down 8% for reported revenue growth and 12% for EPS, while “more importantly,” consensus organic growth estimates for their Biotech segment came down 42%, the analyst tells investors. Currently, the firm views expectations as “appropriately measured for the current environment” and it sees a more attractive entry point into a stock it sees as “a long term compounder undergoing short term/cyclical issues.”